The WHO Solidarity Therapy Study was conducted on 11,266 adult patients in 405 hospitals in more than 30 countries.
For most people, a two-layer fabric mask that covers the face from nose to chin is the best option.
After months of planning and testing a handful of reused drugs that studies from around the world have found useful in treating COVID-1
Based on the data collected from the study, the WHO published an interim report on patient responses to reused medicines (including remdesivir, hydroxychloroquine, lopinavir / ritonavir, and interferon) for treatment with COVID-19. 2,750 volunteers received remdesivir, 954 HCQ, 1,411 lopinavir, 651 interferon plus lopinavir, 1,412 interferon only, and 4,088 placebo (no drug). The study found that these drugs had little or no effect on the outcome of COVID-19 over a period of 28 days.
Some of these drugs have been approved for emergency use by governments of many countries, meaning that patients hospitalized with COVID-19 could be treated with the drug – local laws and licensing requirements. These approvals could now change the basis of the results of the solidarity study, which involved 11,266 patients hospitalized with COVID-19 in 30 countries.
The study looked at how each of these treatments affected mortality, ventilator use, and length of hospital stay in patients hospitalized with COVID-19. No other uses of the drugs for COVID-19 have been investigated, such as treating patients in a COVID-19 infected community or preventing COVID-19.
The results of the study still have to be peer reviewed and have been uploaded to the preprint server medRxiv.
After the WHO, FDA, Oxford University and other countries found that hydroxychloroquine had no beneficial effects on COVID-19 infected patients, they pulled the plug on their ongoing studies. The WHO also canceled studies of the combination of lopinavir and ritonavir with HIV drugs in July after reviewing the progress of those drugs during their interim results.
Soumya Swaminathan, WHO chief scientist, said that during the trials, the HCQ and lopinavir / ritonavir trials were stopped after they were found to be ineffective. However, the other attempts continued as planned.
“We’re looking at what’s next. We are looking at monoclonal antibodies, we are looking at immunomodulators, and we are looking at some of the newer antiviral drugs that have been developed in the past few months,” Swaminathan said Reuters.
Also read: Favipiravir in high doses is effective against COVID-19 in hamsters, HCQ ineffective: study
Remdesivir was the front runner in misappropriated drugs. Various studies have shown a positive recovery rate in patients. According to a report by ReutersData from a U.S. study of remdesivir led by Gilead showed that use of the treatment shortened COVID-19 recovery time by five days in a study of 1,062 patients.
“The emerging data (WHO) appear to be inconsistent, with more robust evidence from multiple randomized, controlled trials published in peer-reviewed journals that confirm the clinical benefits of remdesivir,” Gilead told Reuters.
“We are concerned that the data from this open global study has not been subjected to the rigorous review necessary to enable constructive scientific discussion, especially given the limitations of the study design.”